Recurrent and metastatic clivus chordoma: Systemic palliative therapy retards disease progression

Anti-Cancer Drugs

Volumn 16, Issue 10, 2005, Pages 1139-1143

  Schönegger, Katharina ^a,b   Gelpi, Ellen ^b   Prayer, Daniela ^a   Dieckmann, Karin ^a   Matula, Christian ^a   Hassler, Marco ^a   Hainfellner, Johannes A ^b   Marosi, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clivus chordoma; Multimodal treatment; Pulmonary metastases; Recurrence; Systemic palliative therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOMODULATING AGENT; ISOTRETINOIN; RECOMBINANT ALPHA2B INTERFERON; THALIDOMIDE;

ADULT; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CASE REPORT; CHORDOMA; CLINICAL FEATURE; CLIVUS CHORDOMA; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LEUKOPENIA; LUNG METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; STOMATITIS; TOXICITY; TREATMENT OUTCOME;

CHORDOMA; COMBINED MODALITY THERAPY; CRANIAL FOSSA, POSTERIOR; DISEASE PROGRESSION; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; RECURRENCE; SKULL BASE NEOPLASMS; TREATMENT OUTCOME;

EID: 27644436894     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200511000-00015     Document Type: Article

References (24)

1. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001; 12:1-11.
2. Graham DI, Lantis PL. Chordomas. In: Graham DI, Lantis PL, editors Greenfields neuropathology, New York: Oxford University Press; 2002; vol. 2, pp. 960-964.
3. Ishida T, Dorfman HD. Chondroid chordoma versus low-grade chondrosarcoma of the base of the skull: can immunohistochemistry resolve the controversy? J Neurooncol 1994; 18:199-206.
4. Burger PC. Chordomas. In: Burger PC. editor Tumors of the central nervous system. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology; 1997; vol. 10, pp. 303-305.
5. Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW. Chordomas and cartilaginous tumors at the skull base. Cancer 1973; 32:410-420.
6. Erdem E, Angtuaco EC, Van Hemert R, Park JS, Al-Mefty O. Comprehensive review of intracranial chordoma. Radiographics 2003; 23:995-1009.
7. Pamir MN, Kilic T, Ture U, Ozek MM. Multimodality management of 26 skull-base chordomas with 4-year mean follow-up: experience at a single institution. Acta Neurochir (Wien) 2004; 146:343-354; discussion 354.
8. Naka T, Boltze C, Samii A, Herald C, Ostertag H, Iwamoto Y, et al. Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer 2003; 98:1934-1941.
9. Crockard HA, Steel T, Plowman N, Singh A, Crossman J, Revesz T, et al. A multidisciplinary team approach to skull base chordomas. J Neurosurg 2001; 95:175-183.
10. Kyoshima K, Oikawa S, Kanaji M, Zenisaka H, Takizawa T, Goto T, et al. Repeat operations in the management of clivai chordomas: palliative surgery. J Clin Neurosci 2003; 10:571-578.
11. Jacob HE. Chemotherapy for cranial base tumors. J Neurooncol 1994; 20:327-335.
12. Karakousis CP, Park JJ, Fleminger R, Friedman M. Chordomas: diagnosis and management. Am Surg 1981; 47:497-501.
13. Brodowicz T, Wiltschke C, Kandioler-Eckersberger D, Grunt TW, Rudas M, Schneider SM, et al. Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br J Cancer 1999; 80:1350-1358.
14. Bollag W. Retinoids and interferon: a new promising combination? Br J Haematol 1991; 79(Suppl 1):87-91.
15. Morabito A, Fanelli M, Carillio G, Gattuso D, Sarmiento R, Gasparini G. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol Rep 2004; 11:93-95.
16. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000; 60:273-292.
17. Amato RJ. Thalidomide: an antineoplastic agent. Curr Oncol Rep 2002; 4:56-62.
18. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350:1647-1654.
19. Fleming GF, Heimann PS, Stephens JK, Simon MA, Ferguson MK, Benjamin RS, et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 1993; 72:714-718.
20. Scimeca PG, James-Herry AG, Black KS, Kahn E, Weinblatt ME. Chemotherapeutic treatment of malignant chordoma in children. J Pediatr Hematol Oncol 1996; 18:237-240.
21. La Rocca RV, Morgan KW, Paris K, Baeker TR. Recurrent chondrosarcoma of the cranial base:a durable response to ifosfamide-doxorubicin chemotherapy. J Neurooncol 1999; 41:281-283.
22. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 1997; 54(Suppl 4):15-21.
23. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, et al. Imatinib mesylate in chordoma. Cancer 2004; 101:2086-2097.
24. Fagundes MA, Hug EB, Liebsch NJ, Daly W, Efird J, Munzenrider JE. Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys 1995; 33:579-584.